Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

Merrimack Pharmaceuticals logo

About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)

Advanced Chart

Key Stats

Today's Range
$15.13
$15.13
50-Day Range
$14.65
$15.13
52-Week Range
$11.53
$15.89
Volume
N/A
Average Volume
396,929 shs
Market Capitalization
$223.77 million
P/E Ratio
1.09
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MACK Stock News Headlines

Merrimack Pharma Stock Price History
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
See More Headlines

MACK Stock Analysis - Frequently Asked Questions

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) released its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.14.

Merrimack Pharmaceuticals's stock reverse split before market open on Wednesday, September 6th 2017.The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Merrimack Pharmaceuticals investors own include Rite Aid (RAD), Agenus (AGEN), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Bristol Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
5/10/2019
Today
8/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MACK
Previous Symbol
NASDAQ:MACK
CIK
1274792
Employees
426
Year Founded
2000

Profitability

EPS (Trailing Twelve Months)
$13.87
Trailing P/E Ratio
1.09
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.18 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1.93%
Return on Assets
-1.78%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.78
Quick Ratio
10.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.31 per share
Price / Book
11.55

Miscellaneous

Outstanding Shares
14,790,000
Free Float
10,267,000
Market Cap
$223.77 million
Optionable
Optionable
Beta
1.45

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:MACK) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners